Pharmaceutical

Request for TOC Request for Sample
BUY NOW

Middle East and Africa Primary Angle-Closure Glaucoma Market – Industry Trends and Forecast to 2028

Pharmaceutical | Published Report | Mar 2021 | MEA | 350 Pages | No of Tables: 79 | No of Figures: 36

Report Description

Middle East and Africa Primary Angle-Closure Glaucoma Market, By Disease Type (Acute Angle-Closure Glaucoma and Chronic Angle-Closure Glaucoma), Type (Diagnosis and Treatment), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (South Africa, Egypt, Saudi Arabia, Israel, UAE, Kuwait, Rest of Middle East and Africa) Industry Trends and Forecast to 2028


Market Analysis and Insights: Middle East and Africa Primary Angle-Closure Glaucoma Market

The primary angle-closure glaucoma market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.2% in the forecast period of 2021 to 2028 and is expected to reach USD 340.82 million by 2028. Increasing prevalence of angle-closure glaucoma and advancement in surgical treatment of the disease are the key drivers for primary angle-closure glaucoma market.

Glaucoma is a group of eye conditions that damage the optic nerve and the proper functioning of the optic nerve is necessary for good vision. This damage is often caused by abnormally high pressure in the eye. The primary angle-closure (PAC) is defined as appositional or synechial closure of the anterior chamber angle which can lead to aqueous outflow obstruction and raised IOP in the absence of glaucomatous optic neuropathy.

The increasing population of women and greater female to male ratio in angle-closure glaucoma due to various anatomical and hormonal factors showed the prevalence of the disease in women with increasing women population which is expected to drive the primary angle-closure glaucoma market in the forecasted period. The poor reimbursements are seen as a restraint for the primary angle-closure glaucoma market. The governing body for the approval of products has a significant role in the primary angle-closure glaucoma market growth. The increasing approval of the product for the primary angle-closure glaucoma is expected to boost the market in the forecasted period and will act as opportunities for the primary angle-closure glaucoma market growth. The risks associated with the micro-invasive glaucoma surgery acts as a challenge for the primary angle-closure glaucoma market.

The primary angle-closure glaucoma market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the primary angle-closure glaucoma market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.


Primary Angle-Closure Glaucoma Market Scope and Market Size

The primary angle-closure glaucoma market is segmented on the basis of the disease type, type, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the primary angle-closure glaucoma market is segmented into acute angle-closure glaucoma and chronic angle-closure glaucoma. In 2021, acute angle-closure glaucoma segment is dominating in the primary angle-closure glaucoma market owing to the high incidence cases for acute cases.
  • On the basis of type, the primary angle-closure glaucoma market is segmented into diagnosis and treatment. In 2021, diagnosis segment is dominating in the primary angle-closure glaucoma market due to the primary test and secondary testing options available for the diagnosis and physicians after a proper diagnosis only prefer the medical procedure.
  • On the basis of end user, the primary angle-closure glaucoma market is segmented into hospitals, specialty clinics, ambulatory surgical centers and others. In 2021, hospitals segment is dominating the primary angle-closure glaucoma market as this segment is specialized in conducting various surgical interventions and has a large professional’s portfolio available for giving the proper treatment.
  • On the basis of distribution channel, the primary angle-closure glaucoma market is segmented into direct tender, retail sales and others. In 2021, direct tender segment dominates the primary angle-closure glaucoma market as they are the primary source of procurement of diagnostic and surgical devices by healthcare organizations and specialty clinics.

Primary Angle-Closure Glaucoma Market Country Level Analysis

The primary angle-closure glaucoma market is analysed and market size information is provided by the country, disease type, type, end user and distribution channel as referenced above.

The countries covered in Middle East and Africa primary angle-closure glaucoma market report are South Africa, Egypt, Saudi Arabia, Israel, UAE, Kuwait, Rest of Middle East and Africa.

Middle East and Africa is expected to grow with the substantial growth rate in the forecast period of 2020 to 2028 as Middle East and Africa counties are major developing countries and focus on increasing usage of treatment by surgical procedure and rising awareness about it. South Africa is expected to dominate in the market due to increasing prevalence of angle-closure glaucoma in the country.

 The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Increase Government Initiatives Towards Glaucoma And Recent Approval By Governing Bodies Are Creating New Opportunities In The Primary Angle-Closure Glaucoma Market

Primary angle-closure glaucoma market also provides you with detailed market analysis for every country growth in particular industry with angle-closure glaucoma surgical and diagnosis product sales, impact of advancement in the primary angle-closure glaucoma and changes in regulatory scenarios with their support for the primary angle-closure glaucoma Market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Primary Angle-Closure Glaucoma Market Share Analysis

The primary angle-closure glaucoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to primary angle-closure glaucoma market.

The major companies in primary angle-closure glaucoma market are Johnson & Johnson Vision Care, Inc. (a subsidiary of Johnson & Johnson Services Inc.), Bausch & Lomb (a subsidiary of Bausch Health), Alcon Inc., NIDEK CO., LTD, Allergan (a subsidiary of AbbVie Inc.), BVI, Oertli Instrumente AG, Reichert Inc., among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the primary angle-closure glaucoma market.

For instance,

  • In June 2020, Johnson & Johnson Vision Care, Inc. has announced to donate to Optometry Cares – The American Optometric Association (AOA) Foundation and the American Academy of Optometry Foundation. The total amount of USD 0.30 million were donated by the company for the practitioner in their support to provide eye care to the community affected by COVID-19.

Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the primary angle-closure glaucoma which also provides the benefits for organisations to improve their offerings for primary angle-closure glaucoma market.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 EPIDEMIOLOGY

5 REGULATORY FRAMEWORK

6 PIPELINE ANALYSIS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA

7.1.2 INCREASING WOMEN POPULATION

7.1.3 RISE IN GERIATRIC POPULATION

7.1.4 ADVANCEMENTS IN SURGICAL TREATMENT OF THE DISEASE

7.1.5 INCREASED ECONOMIC BURDEN

7.2 RESTRAINTS

7.2.1 HIGH SURGICAL COSTS OF PACG

7.2.2 INADEQUATE REIMBURSEMENT SCENARIO

7.2.3 DELAYED AND MISDIAGNOSIS OF PACG

7.3 OPPORTUNITIES

7.3.1 INCREASING GOVERNMENT INITIATIVES TOWARDS GLAUCOMA

7.3.2 RECENT APPROVAL BY GOVERNING BODIES

7.3.3 INCREASING INCIDENCES IN EMERGING MARKET

7.3.4 RAPID TRANSITION FROM PACG MEDICATION TO SURGERIES

7.4 CHALLENGES

7.4.1 RISKS ASSOCIATED WITH SURGICAL PROCEDURES

7.4.2 LACK OF SKILLED PROFESSIONALS WITH ADEQUATE KNOWLEDGE

7.4.3 LIMITED ACCESS TO TREATMENT

8 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET

8.1 IMPACT ON PRICE

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC DECISION BY MANUFACTURERS

8.5 CONCLUSION

9 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE

9.1 OVERVIEW

9.2 ACUTE ANGLE-CLOSURE GLAUCOMA MARKET

9.3 CHRONIC ANGLE-CLOSURE GLAUCOMA MARKET

10 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE

10.1 OVERVIEW

10.2 DIAGNOSIS

10.2.1 PRIMARY TEST

10.2.1.1 GONIOSCOPY EXAMINATION

10.2.1.2 SLIT-LAMP EXAMINATION

10.2.1.3 AUTOMATIC STATIC PERIMETRY

10.2.2 SECONDARY TEST

10.2.2.1 ULTRASOUND BIOMICROSCOPY

10.2.2.2 ANTERIOR SEGMENT OPTICAL COHERENCE TOMOGRAPHY (OCT)

10.2.2.3 RETINAL OCT

10.2.2.4 FUNDOSCOPY

10.2.2.5 OTHERS

10.3 TREATMENT

10.3.1 SURGICAL IRIDECTOMY

10.3.2 TRABECULECTOMY

10.3.3 MICRO INVASIVE GLAUCOMA TECHNIQUE (MIGS)

10.3.4 GONIOTOMY

10.3.5 OTHERS

11 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 AMBULATORY SURGICAL CENTERS

11.4 SPECIALTY CLINICS

11.5 OTHERS

12 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL SALES

12.4 OTHERS

13 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY GEOGRAPHY

13.1 MIDDLE EAST AND AFRICA

13.1.1 SOUTH AFRICA

13.1.2 EGYPT

13.1.3 SAUDI ARABIA

13.1.4 ISRAEL

13.1.5 UAE

13.1.6 KUWAIT

13.1.7 REST OF MIDDLE EAST AND AFRICA

14 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

15 SWOT

16 COMPANY PROFILES

16.1 JOHNSON & JOHNSON VISION CARE, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 BAUSCH & LOMB INCORPORATED (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 ALCON INC.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 ZEISS INTERNATIONAL

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 NOVA EYE MEDICAL LIMITED

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENTS

16.6 NIDEK CO., LTD

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENTS

16.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 APPASAMY ASSOCIATES

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 AUROLAB

16.9.1 COMPANY SNAPSHOT

16.9.2 PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENT

16.1 BVI

16.10.1 COMPANY SNAPSHOT

16.10.2 PRODUCT PORTFOLIO

16.10.3 RECENT DEVELOPMENTS

16.11 LIGHTMED

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVELOPMENTS

16.12 LUNEAU TECHNOLOGY USA

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENT

16.13 MEDISONIC EQUIPMENTS PVT. LTD.

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENT

16.14 MICROSURGICAL TECHNOLOGY

16.14.1 COMPANY SNAPSHOT

16.14.2 PRODUCT PORTFOLIO

16.14.3 RECENT DEVELOPMENTS

16.15 NEW VISION

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENTS

16.16 NEW WORLD MEDICAL, INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENTS

16.17 OERTLI INSTRUMENTE AG

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENTS

16.18 OMNI LENS

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENT

16.19 REICHERT, INC. (A BUSINESS UNIT OF AMETEK.INC.)

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENTS

16.2 SIGHT SCIENCES, INC.

16.20.1 COMPANY SNAPSHOT

16.20.2 PRODUCT PORTFOLIO

16.20.3 RECENT DEVELOPMENTS

17 QUESTIONNAIRE

18 RELATED REPORTS

List of Table

TABLE 1 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, PIPELINE ANALYSIS

TABLE 2 NUMBER OF OPHTHALMOLOGISTS/MILLION POPULATIONS

TABLE 3 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA ACUTE-ANGLE CLOSURE GLAUCOMA IN PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA CHRONIC ANGLE-CLOSURE GLAUCOMA IN PRIMARY ANGLE CLOSURE GLAUCOMA MARKET,BY REGION, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA HOSPITALS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA OTHERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA DIRECT TENDER IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA RETAIL SALES IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA OTHERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 31 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 32 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 33 SOUTH AFRICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 34 SOUTH AFRICA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 35 SOUTH AFRICA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 36 SOUTH AFRICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 37 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 38 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 39 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 40 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 41 EGYPT DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 42 EGYPT PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 43 EGYPT SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 44 EGYPT TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 45 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 46 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 47 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 48 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 49 SAUDI ARABIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 50 SAUDI ARABIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 51 SAUDI ARABIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 52 SAUDI ARABIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 53 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 54 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 55 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 56 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 57 ISRAEL DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 58 ISRAEL PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 59 ISRAEL SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 60 ISRAEL TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 61 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 62 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 63 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 64 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 65 UAE DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 66 UAE PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 67 UAE SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 68 UAE TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 69 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 70 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 71 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 72 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 73 KUWAIT DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 74 KUWAIT PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 75 KUWAIT SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 76 KUWAIT TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 77 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 78 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 79 REST OF MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET : DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA AND ADVANCEMENT IN SURGICAL TREATMENT OF THE DISEASE ARE DRIVING THE MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 ACUTE ANGLE-CLOSURE GLAUCOMA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET

FIGURE 15 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020

FIGURE 16 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)

FIGURE 17 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, CAGR (2020-2028)

FIGURE 18 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 19 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020

FIGURE 20 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE 2020-2028 (USD MILLION)

FIGURE 21 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 22 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 23 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020

FIGURE 24 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020-2028 (USD MILLION)

FIGURE 25 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, CAGR (2021-2028)

FIGURE 26 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, LIFELINE CURVE

FIGURE 27 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 28 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 29 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 30 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION, LIFELINE CURVE

FIGURE 31 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SNAPSHOT (2020)

FIGURE 32 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020)

FIGURE 33 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2021 & 2028)

FIGURE 34 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020 & 2028)

FIGURE 35 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY TYPE (2021-2028)

FIGURE 36 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY SHARE 2020 (%)

View Infographics

FIGURE 1 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET : DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA AND ADVANCEMENT IN SURGICAL TREATMENT OF THE DISEASE ARE DRIVING THE MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 ACUTE ANGLE-CLOSURE GLAUCOMA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET

FIGURE 15 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020

FIGURE 16 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)

FIGURE 17 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, CAGR (2020-2028)

FIGURE 18 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 19 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020

FIGURE 20 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE 2020-2028 (USD MILLION)

FIGURE 21 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 22 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 23 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020

FIGURE 24 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020-2028 (USD MILLION)

FIGURE 25 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, CAGR (2021-2028)

FIGURE 26 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, LIFELINE CURVE

FIGURE 27 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 28 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 29 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 30 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION, LIFELINE CURVE

FIGURE 31 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SNAPSHOT (2020)

FIGURE 32 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020)

FIGURE 33 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2021 & 2028)

FIGURE 34 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020 & 2028)

FIGURE 35 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY TYPE (2021-2028)

FIGURE 36 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY SHARE 2020 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 8500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19